Key result
Elevated synthetic integral extracellular volume was independently associated with an increased risk of major adverse cardiovascular events in type 2 diabetes patients with acute myocardial infarction.
Why the study?
The prognostic role of extracellular volume (ECV) and the feasibility of synthetic ECV without blood sampling were unknown in diabetes patients with acute myocardial infarction.
Does elevated synthetic extracellular volume (ECV) measured by CMR predict major adverse cardiovascular events in T2DM patients with acute myocardial infarction?
Cohort (n=157)
No
Does elevated synthetic extracellular volume (ECV) measured by CMR predict major adverse cardiovascular events in T2DM patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Synthetic ECV derived from CMR without blood sampling is highly consistent with conventional ECV and serves as an independent predictor of MACE in T2DM patients with AMI.
Background: Extracellular volume (ECV) is an important marker of myocardial fibrosis. However, the prognostic role of ECV in diabetes patients is unknown. In addition, synthetic ECV without blood sampling has not been reported in diabetes cohorts. This study investigated the establishment and validation of synthetic ECV and its prognostic value in type 2 diabetes mellitus (T2DM) patients with acute myocardial infarction (AMI). Methods: This single-center retrospective study included T2DM patients with AMI who completed cardiac magnetic resonance (CMR) during hospitalization. The patients were randomly divided into a derivation group and a validation group. MACE included all-cause death, recurrent MI, stroke, or heart failure. ECV in integral (Integral ECV), non-myocardial infarction region (NMI-ECV), and myocardial infarction region (MI-ECV) was obtained by CMR. Results: The study included 157 patients, with a median time from admission to CMR of 4 days. Bland-Altman and Pearson analysis showed good consistency and correlation between conventional ECV and synthetic ECV. Cox regression showed that Integral ECV (HR=1.07; 95%CI: 1.01 ~ 1.13, p = 0.023), MI-ECV (HR=1.03; 95%CI: 1.00 ~ 1.07, p = 0.024), and NMI-ECV (HR=1.07; 95%CI: 1.00 ~ 1.14, p = 0.039) were independently associated with MACE in different models. Kaplan-Meier analysis indicated that patients with a high synthetic ECV had a significantly higher MACE risk. Conclusions: Synthetic ECV is strongly consistent and correlated with conventional ECV in T2DM patients with AMI. Elevated synthetic ECV is an independent risk factor for MACE in T2DM patients with AMI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a cohort in Type 2 diabetes mellitus with acute myocardial infarction (n=157). Elevated synthetic extracellular volume (ECV) vs. Lower synthetic ECV was evaluated on Major adverse cardiovascular events (MACE) (HR 1.07, 95% CI 1.01-1.13, p=0.023). Elevated synthetic integral extracellular volume was independently associated with an increased risk of major adverse cardiovascular events in type 2 diabetes patients with acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: